12 Ovarian Cancer Research Foundation 12 Ovarian Cancer Research Foundation Our Impact to date As our research continues, project successes and failures all contribute tobuilding a better understanding of the disease and how best to tackle it.Key progress and milestones over the past decade are depicted in the timeline below. Simson Cards commences sponsorship relationship Discovery of a potential biomarker (CXCL10) Discovery of a novel drug target (Annexin A2) Identification of new drug targets (proteins ROR1 and ROR2) Georg Jensen commences sponsorship relationship Discovery of three potential biomarkers (autoantibodies) The first PARP inhibitor is approved for BRCA patients Development begins for an early detection test - ARt (Active Ratio Test) Discovery of 9 potential biomarkers (proteins) OCRF shifts funding to grant application process Identification of potential causes of chemo-resistance Validation of an early detection biomarker in a large international patient cohort Major events in OCRF history Major events in OvCa research OCRF research outcomes 2010 2011 2013 2014 2015 2016 2017 2018 2019